ES2399651T8 - Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena - Google Patents

Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena

Info

Publication number
ES2399651T8
ES2399651T8 ES09793940T ES09793940T ES2399651T8 ES 2399651 T8 ES2399651 T8 ES 2399651T8 ES 09793940 T ES09793940 T ES 09793940T ES 09793940 T ES09793940 T ES 09793940T ES 2399651 T8 ES2399651 T8 ES 2399651T8
Authority
ES
Spain
Prior art keywords
hyperinsullemic
pasireotide
hypoglycaemia
endogenous
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09793940T
Other languages
English (en)
Other versions
ES2399651T3 (es
Inventor
Herbert Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2399651T3 publication Critical patent/ES2399651T3/es
Publication of ES2399651T8 publication Critical patent/ES2399651T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES09793940T 2008-07-08 2009-07-07 Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena Active ES2399651T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159918 2008-07-08
EP08159918 2008-07-08
PCT/EP2009/058573 WO2010003939A1 (en) 2008-07-08 2009-07-07 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Publications (2)

Publication Number Publication Date
ES2399651T3 ES2399651T3 (es) 2013-04-02
ES2399651T8 true ES2399651T8 (es) 2020-11-18

Family

ID=39876604

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09793940T Active ES2399651T3 (es) 2008-07-08 2009-07-07 Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena

Country Status (12)

Country Link
US (2) US9314508B2 (es)
EP (1) EP2310042B1 (es)
JP (1) JP5721624B2 (es)
CY (1) CY1113726T1 (es)
DK (1) DK2310042T3 (es)
ES (1) ES2399651T3 (es)
HR (1) HRP20130145T1 (es)
PL (1) PL2310042T3 (es)
PT (1) PT2310042E (es)
SI (1) SI2310042T1 (es)
SM (1) SMT201300030B (es)
WO (1) WO2010003939A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
LT3456340T (lt) 2007-01-08 2022-05-10 The Trustees Of The University Of Pennsylvania Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016141111A1 (en) * 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
SMT202100668T1 (it) * 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja) 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤
GB201816637D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393050A (en) 1981-04-29 1983-07-12 The Salk Institute For Biological Studies Analogs of extended N-terminal somatostatin
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7094753B2 (en) * 2001-11-21 2006-08-22 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Somatostatin analog and uses thereof
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
EP1689429A1 (en) * 2003-11-25 2006-08-16 Novartis AG Biomarkers for the efficacy of somatostatin analogue treatment
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL2310042T3 (pl) 2013-05-31
US9867864B2 (en) 2018-01-16
EP2310042B1 (en) 2012-12-05
EP2310042A1 (en) 2011-04-20
DK2310042T3 (da) 2013-03-04
US9314508B2 (en) 2016-04-19
US20160184388A1 (en) 2016-06-30
WO2010003939A1 (en) 2010-01-14
SI2310042T1 (sl) 2013-03-29
SMT201300030B (it) 2013-07-09
JP2011527309A (ja) 2011-10-27
ES2399651T3 (es) 2013-04-02
PT2310042E (pt) 2013-03-11
CY1113726T1 (el) 2016-06-22
JP5721624B2 (ja) 2015-05-20
HRP20130145T1 (hr) 2013-03-31
US20110124555A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
PT2280973E (pt) Análogos de carba-nucleósido para tratamento antiviral
ES2525801T8 (es) Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
PL2310042T3 (pl) Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
BRPI0907950A2 (pt) Tratamento de hiperglicemia com 25-hidroxivitamina d3
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"
BRPI0923377A2 (pt) Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
ES1065640Y (es) Aparato para el alargamiento del pene